γδT细胞在肝细胞癌中作用的研究进展

doi:10.16139/j.1007-9610.2018.03.021

摘要/Abstract

中图分类号:

R735.7

祝桂琦, 王彪, 杨怡, 代智. γδT细胞在肝细胞癌中作用的研究进展[J]. 外科理论与实践, 2018, 23(03): 289-292.

[1] Forner A, Llovet JM, Bruix J.Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245-1255.
[2] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell,2011,144(5):646-674.
[3] Rinninella E, Cerrito L, Spinelli I, et al.Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives[J]. J Clin Transl Hepatol,2017,5(3):235-248.
[4] Marx J.Cancer research. Inflammation and cancer: the link grows stronger[J]. Science,2004,306(5698):966-968.
[5] Prinz I, Silva-Santos B, Pennington DJ.Functional deve-lopment of γδ T cells[J]. Eur J Immunol,2013,43(8):1988-1994.
[6] Philip M, Rowley DA, Schreiber H.Inflammation as a tumor promoter in cancer induction[J]. Semin Cancer Biol,2004,14(6):433-439.
[7] Chien YH, Meyer C, Bonneville M.γδ T cells: first line of defense and beyond[J]. Annu Rev Immunol,2014,32:121-155.
[8] Kabelitz D, Wesch D, He W.Perspectives of gammadelta T cells in tumor immunology[J]. Cancer Res,2007, 67(1):5-8
[9] Deng Y, Du Y, Zhang Q, et al.Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma[J]. Cancer Lett,2014,343(2):161-171.
[10] Mantovani A, Allavena P, Sica A, et al.Cancer-related inflammation[J]. Nature,2008,454(7203):436-444.
[11] Campillo JA, Martinez-Escribano JA, Minguela A, et al.Increased number of cytotoxic CD3+ CD28- gammadelta T cells in peripheral blood of patients with cutaneous malignant melanoma[J]. Dermatology,2007,214(4):283-288.
[12] Patin EC, Soulard D, Fleury S, et al.Type Ⅰ IFN receptor signaling controls IL7-dependent accumulation and activi-ty of protumoral IL17A-producing γδ T cells in breast cancer[J]. Cancer Res,2018,78(1):195-204.
[13] Wang X, Tian Z.γδ T cells in liver diseases[J]. Front Med,2018,12(3):262-268.
[14] Hayday AC.γδ cells: a right time and a right place for a conserved third way of protection[J]. Annu Rev Immunol,2000,18:975-1026.
[15] Albini A, Bruno A, Noonan DM, et al.Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy[J]. Front Immunol,2018,9:527.
[16] Ribot JC, Serre K, Silva-Santos B.Developmental and functional assays to study murine and human γδ T cells[J]. Methods Mol Biol,2017,1514:257-267.
[17] Cai XY, Wang JX, Yi Y, et al.Low counts of γδ T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection[J]. Asian Pac J Cancer Prev,2014,15(2):775-780.
[18] Sugie T, Suzuki E, Yamauchi A, et al.Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer[J]. Breast,2018,38:114-119.
[19] 陈复兴, 刘军权, 冯霞, 等. 人末梢血γδT细胞对消化系统肿瘤细胞的杀伤作用[J]. 世界华人消化杂志,2007,15(14):1591-1595.
[20] Wakita D, Sumida K, Iwakura Y, et al.Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis[J]. Eur J Immunol,2010;40(7):1927-1937.
[21] Ma S, Cheng Q, Cai Y, et al.IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma[J]. Cancer Res,2014,74(7):1969-1982.
[22] Chen J, Fan Y, Cui B, et al.HMGN2: An antitumor effector molecule of γδT cells[J]. J Immunother,2018,41(3):118-124.
[23] Wang J, Lin C, Li H, et al.Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer[J]. Oncoimmunology,2017, 6(11):e1353858.
[24] 刘玲. 观察分析肝硬化及肝癌患者γδT细胞的表达[J]. 临床医药文献电子杂志,2016,3(35):6979.
[25] Yi Y, He HW, Wang JX, et al.The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner[J]. J Hepatol,2013,58(5):977-983.
[26] Mangan BA, Dunne MR, O′Reilly VP, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vdelta3 T cells[J]. J Immunol,2013,191(1):30-34.
[27] Lalazar G, Preston S, Zigmond E, et al.Glycolipids as immune modulatory tools[J]. Mini Rev Med Chem,2006, 6(11):1249-1253.
[28] Harly C, Peyrat MA, Netzer S, et al.Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells[J]. Blood,2011,117(10):2864-2873.
[29] Pang YL, Zhang HG, Peng JR, et al.The immunosuppressive tumor microenvironment in hepatocellular carcinoma[J]. Cancer Immunol Immunother,2009,58(6):877-886.
[30] Cui J, Wang N, Zhao H, et al.Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma[J]. Int J Cancer,2014,134(2):342-351.

γδT细胞在肝细胞癌中作用的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[2]	陈晓娟, 张雯, 蔡瑜. 经导管脾动脉栓塞术治疗胰源性门静脉高压致消化道出血(附1例报告)[J]. 外科理论与实践, 2022, 27(04): 359-362.
[3]	赵含丹, 许利军. 人类免疫缺陷病毒相关隐球菌脑膜炎的诊治现状和挑战[J]. 诊断学理论与实践, 2022, 21(04): 419-424.
[4]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[5]	陈志敏, 刘波, 何浩岚, 何耀祖, 冯理智, 刘新华, 张坚生, 蔡卫平, 李凌华. 133例艾滋病合并马尔尼菲篮状菌病死亡病例分析[J]. 诊断学理论与实践, 2022, 21(04): 444-449.
[6]	胡静静, 吕海伟, 荀静娜, 沈银忠, 刘莉, 卢洪洲. 2012年至2021年上海市艾滋病合并分枝杆菌感染患者的菌种分布特征[J]. 诊断学理论与实践, 2022, 21(04): 450-455.
[7]	汤建平, 龚邦东. 干燥综合征的诊治现状、挑战和思考[J]. 诊断学理论与实践, 2022, 21(03): 291-298.
[8]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[9]	牟兴, 叶倩仪, 卢红娟, 徐沪济, 吴歆. 季节变化对风湿病发病机制及病情活动的影响[J]. 诊断学理论与实践, 2022, 21(03): 304-311.
[10]	刘萍, 肖园, 王歆琼, 陆亭伟, 赵雪松, 杨媛艳. Wiskott-Aldrich综合征合并克罗恩病一例并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 349-354.
[11]	赵东宝. 风湿病继发骨质疏松症研究进展[J]. 内科理论与实践, 2022, 17(03): 181-185.
[12]	王宏智, 袁昳玮. 类风湿关节炎的慢病管理[J]. 内科理论与实践, 2022, 17(03): 202-207.
[13]	张春丽, 徐静, 潘晓霞, 胡晓帆, 李娅. IgG4相关肾病临床及病理特征分析[J]. 内科理论与实践, 2022, 17(03): 214-219.
[14]	徐娜娜, 吴涛, 毛东锋, 薛锋, 刘文慧, 王宗慧, 白海. 肾脏原发髓外浆细胞瘤1例[J]. 内科理论与实践, 2022, 17(03): 253-255.
[15]	孔秀芳, 姜林娣. 大动脉炎发病机制及诊疗研究进展[J]. 内科理论与实践, 2022, 17(03): 262-266.